MorphoSys
(NASDAQ:MOR)
$3.93
At close: Dec 1(Delayed 15-Minutes)
Get Real Time Here
$4.16
0.2300[5.85%]
PreMarket: 8:44AM EDT
Day Range- - -52 Wk Range3.7 - 10.25Open / Close- / -Float / Outstanding- / 136.9M
Vol / Avg.- / 86.1KMkt Cap538.1MP/E-50d Avg. Price4.78
Div / Yield-Payout Ratio-Total Float-EPS-0.9

MorphoSys Stock (NASDAQ:MOR), Quotes and News Summary

MorphoSys Stock (NASDAQ: MOR) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range3.7 - 10.25Open / Close- / -Float / Outstanding- / 136.9M
Vol / Avg.- / 86.1KMkt Cap538.1MP/E-50d Avg. Price4.78
Div / Yield-Payout Ratio-Total Float-EPS-0.9
Seeking Alpha - Nov 17, 2022, 11:13AM
InvestorsObserver - Nov 15, 2022, 11:58AM
InvestorsObserver - Nov 14, 2022, 5:43AM
InvestorsObserver - Nov 9, 2022, 7:49AM
InvestorsObserver - Nov 3, 2022, 10:04AM
InvestorsObserver - Nov 2, 2022, 9:18AM
InvestorsObserver - Oct 26, 2022, 7:26AM
InvestorsObserver - Oct 25, 2022, 8:10AM
Seeking Alpha - Oct 24, 2022, 1:02PM
InvestorsObserver - Oct 18, 2022, 12:39PM
Seeking Alpha - Sep 28, 2022, 8:33AM
InvestorsObserver - Sep 22, 2022, 8:24AM
InvestorsObserver - Sep 15, 2022, 8:11AM
InvestorsObserver - Aug 22, 2022, 8:45AM
InvestorsObserver - Aug 18, 2022, 9:48AM
Sector: Health Care.Industry: Biotechnology
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Earnings

see more
Q3 2022Est.ActualSurprise
EPS-0.400-0.910 -0.5100
REV69.200M96.579M27.379M
Q2 2022Est.ActualSurprise
EPS-1.830
REV46.520M63.307M16.787M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy MorphoSys (MOR) stock?

A

You can purchase shares of MorphoSys (NASDAQ: MOR) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for MorphoSys (MOR) stock?

A

The latest price target for MorphoSys (NASDAQ: MOR) was reported by JMP Securities on Friday, November 18, 2022. The analyst firm set a price target for 15.00 expecting MOR to rise to within 12 months (a possible 281.68% upside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for MorphoSys (MOR)?

A

The stock price for MorphoSys (NASDAQ: MOR) is $3.93 last updated December 1, 2022, 9:00 PM UTC.

Q

Does MorphoSys (MOR) pay a dividend?

A

There are no upcoming dividends for MorphoSys.

Q

When is MorphoSys (NASDAQ:MOR) reporting earnings?

A

MorphoSys’s Q3 earnings are confirmed for Wednesday, November 16, 2022.

Q

Is MorphoSys (MOR) going to split?

A

There is no upcoming split for MorphoSys.

Q

What sector and industry does MorphoSys (MOR) operate in?

A

MorphoSys is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.